Clinical Study on Options of Medication Regimen in Treatment of Refractory Obsessive-Compulsive Disorder Patients
Condition:   Obsessive-Compulsive Disorder Interventions:   Drug: Sertraline 200 milligram(mg);   Drug: Sertraline 300 milligram(mg);   Drug: Fluvoxamine;   Drug: Venlafaxine;   Drug: Augment with Memantine;   Drug: Augment with Aripiprazole Sponsors:   Shanghai Mental Health Center;   The first specialized hospital of harbin;   Guizhou Provincial People's Hospital;   First Affiliated Hospital of Jinan University; &n...
Source: ClinicalTrials.gov - September 7, 2020 Category: Research Source Type: clinical trials

Atypical Antipsychotics Influence on the Safety of the Heart and Monitoring Indicators Model Building
Condition:   Schizophrenia Interventions:   Drug: Risperidone;   Drug: Aripiprazole;   Drug: Ziprasidone;   Drug: Amisulpride;   Drug: Quetiapine Sponsors:   Shanghai Mental Health Center;   Shanghai Jiao Tong University School of Medicine Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - June 24, 2020 Category: Research Source Type: clinical trials

Observational Study on the Effect of Switch to Lurasidone in Subjects With Schizophrenia "
Condition:   Schizophrenia Interventions:   Drug: Lurasidone;   Drug: aripiprazole, olanzapine, quetiapine or risperidone Sponsor:   Aziende Chimiche Riunite Angelini Francesco S.p.A Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 18, 2020 Category: Research Source Type: clinical trials

Intramuscular Ketamine Versus Aripiprazole and Escitalopram in the Treatment of Resistant Depression
Condition:   Depressive Disorder Interventions:   Drug: Ketamine;   Diagnostic Test: Cognition;   Other: Suicide risk;   Other: Depression thoughts;   Other: Quality of life and disability;   Other: Clinical and epidemiological factors;   Device: Safety of ketamine IM;   Other: Tolerability of ketamine IM Sponsor:   University of Sao Paulo Enrolling by invitation (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 21, 2020 Category: Research Source Type: clinical trials

Aripiprazole Lauroxil for Preventing Psychotic Relapse After an Initial Schizophrenia Episode
Conditions:   Schizophrenia;   Schizoaffective Disorder, Depressive Type;   Schizophreniform Disorder Interventions:   Drug: Aripiprazole Lauroxil;   Drug: ARI-ORAL;   Drug: AL-NCD Sponsors:   University of California, Los Angeles;   Alkermes, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 18, 2019 Category: Research Source Type: clinical trials